Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonged MMF and Truncated CSP for GVHD Prevention
NCT00078858Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2003
- Primary completion
- Jan 2006
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of mycophenolate mofetil in hematologic malignancy and renal cell carcinoma (RCC), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Incidence of life-threatening GVHD at 1 year. Started Sep 2003; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
hematologic malignancyrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00078858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00078858.